Welcome to our dedicated page for HILS news (Ticker: HILS), a resource for investors and traders seeking the latest updates and insights on HILS stock.
Hillstream BioPharma news covers the biotechnology issuer's transition into Tharimmune, including the corporate name and ticker change, clinical-stage licensing activity, and pipeline repositioning from oncology biologics toward inflammatory and immunology-related therapeutic candidates.
Recurring announcements include TH104 and AV104 chronic pruritis development, conference presentations, and historical oncology program updates involving HSB-3215, HER2/HER3 antibodies, Quatramer and Quatrabody technology, Picobodies, Minotaur Therapeutics and OmniAb.
Hillstream BioPharma (NASDAQ:HILS) has announced significant upcoming events, including a R&D Day on February 24, 2022, and a Business Review on February 14, 2022. The R&D Day will showcase emerging pipeline assets and anticipated milestones, focusing on innovative therapeutic candidates targeting ferroptosis, an anti-cancer mechanism for treating drug-resistant cancers. The company's lead candidate, HSB-1216, showed positive results in a clinical pilot study in Germany, targeting various solid tumors. The company aims to advance HSB-1216 into further clinical trials this year.
Hillstream BioPharma, Inc. (NASDAQ:HILS) announced acceptance of an abstract on HSB-510, a novel dual-targeted HDAC6/PI3K-delta inhibitor, for presentation at the 2022 AACR Annual Meeting. This drug targets ferroptosis to combat drug-resistant cancers, showing promise in preclinical studies by significantly downregulating the growth of triple-negative breast cancer (TNBC) cells. HSB-510 is encapsulated in a proprietary Quatramer formulation with potential for effective therapy targeting multiple MYC-dependent tumors. The company plans IND-enabling studies in 2023.
Hillstream BioPharma (Nasdaq:HILS) has announced a collaboration with University of Massachusetts Chan Medical School aimed at identifying a novel chemogenetic biomarker profile for HSB-1216, its lead anti-cancer compound targeting iron-mediated cell death. This collaboration will leverage CRISPR genome editing to advance the Hillstream Ferroptomic Atlas, enhancing understanding of the drug's effect on drug-resistant tumors. The partnership involves Dr. Michael J. Lee's lab, which specializes in cancer cell signaling pathways. The expected outcomes include insights into the compound's mechanism and potential biomarkers for clinical trials.